Trial Profile
Low- and high-dose budesonide/formoterol administered via a DuoResp Spiromax inhaler or a Symbicort Turbuhaler in volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 25 Oct 2013
Price :
$35
*
At a glance
- Drugs Budesonide/formoterol (Primary)
- Indications Asthma; Chronic obstructive pulmonary disease
- Focus Pharmacodynamics
- 25 Oct 2013 New trial record
- 11 Sep 2013 Results presented at the 23rd Annual Congress of the European Respiratory Society.